

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT2/22 - Direct Antiglobulin Test

Deadline: 18.11.2022

Key: >>> ... marks correct (expected) result
> ... marks conditionally correct (acceptable) result
± ... marks the result not evaluated

N ... number of the results
Nrel ... relative number of the results

Test

Sample	Group	N	Result	N _{rel}
(1001) DAT (direct Coombs test)				
1	(0) not specified	>	1 Positive (4+)	1,2 %
	(14) Bio-Rad	>	3 Positive (2+)	3,5 %
		>>>	35 Positive (3+)	41 %
		>	7 Positive (4+)	8,1 %
	(17) Biogema	>>>	1 Positive (3+)	1,2 %
	(40) Ortho Clinical Diagnostics	>>>	2 Positive (3+)	2,3 %
		>	1 Positive (4+)	1,2 %
	(80) DiaMed	>	1 Positive (2+)	1,2 %
		>>>	6 Positive (3+)	7,0 %
		>	3 Positive (4+)	3,5 %
	(159) Grifols	>>>	22 Positive (3+)	26 %
		>	3 Positive (4+)	3,5 %
	(173) Sanguin	>	1 Positive (2+)	1,2 %
	----- Total per sample: n = 86 ----- Success: 100 % -----			
2	(0) not specified	>	1 Positive (3+)	1,2 %
	(14) Bio-Rad	>>>	31 Positive (2+)	36 %
		>	14 Positive (3+)	16 %
	(17) Biogema	>	1 Positive (3+)	1,2 %
	(40) Ortho Clinical Diagnostics	>	1 Positive (1+)	1,2 %
		>	2 Positive (3+)	2,3 %
	(80) DiaMed	>>>	6 Positive (2+)	7,0 %
		>	3 Positive (3+)	3,5 %
		>	1 Positive (4+)	1,2 %
	(159) Grifols	>	1 Positive (1+)	1,2 %
		>>>	8 Positive (2+)	9,3 %
		>	15 Positive (3+)	17 %
		>	1 Positive (4+)	1,2 %
	(173) Sanguin	>	1 Positive (1+)	1,2 %
----- Total per sample: n = 86 ----- Success: 100 % -----				
Total success: 100 %				

(1002) Sensitization specificity anti-IgG

1	(0) not specified	>	1 Positive (4+)	2,4 %
	(14) Bio-Rad	>>>	18 Positive (3+)	43 %
		>	6 Positive (4+)	14 %
	(80) DiaMed	>	1 Positive (2+)	2,4 %
		>>>	5 Positive (3+)	12 %
		>	4 Positive (4+)	9,5 %
	(159) Grifols	>>>	6 Positive (3+)	14 %
>		1 Positive (4+)	2,4 %	
----- Total per sample: n = 42 ----- Success: 100 % -----				
2	(0) not specified	>>>	1 Positive (3+)	2,4 %
	(14) Bio-Rad	>	14 Positive (2+)	33 %
		>>>	10 Positive (3+)	24 %
	(80) DiaMed	>	7 Positive (2+)	17 %
		>>>	2 Positive (3+)	4,8 %
		>	1 Positive (4+)	2,4 %
	(159) Grifols	>	1 Positive (1+)	2,4 %
>		1 Positive (2+)	2,4 %	
	>>>	5 Positive (3+)	12 %	
----- Total per sample: n = 42 ----- Success: 100 % -----				
Total success: 100 %				

(1003) Sensitization specificity anti-IgA

1	(14) Bio-Rad	>>>	22 Negative	71 %
	(80) DiaMed	>>>	9 Negative	29 %
----- Total per sample: n = 31 ----- Success: 100 % -----				
2	(14) Bio-Rad	>>>	22 Negative	71 %
	(80) DiaMed	>>>	9 Negative	29 %
----- Total per sample: n = 31 ----- Success: 100 % -----				
Total success: 100 %				

(1004) Sensitization specificity anti-IgM

1	(14) Bio-Rad	>>>	22 Negative	71 %
	(80) DiaMed	>>>	9 Negative	29 %
----- Total per sample: n = 31 ----- Success: 100 % -----				
2	(14) Bio-Rad	>>>	22 Negative	71 %

EQA round: PAT2/22 - Direct Antiglobulin Test

Deadline: 18.11.2022

Test		N	Result	N _{rel}
Sample	Group			
2	(80) DiaMed	>>>	9 Negative	29 %
Total per sample: n = 31		Success: 100 %		
Total success: 100 %				
(1005) Sensitization specificity anti-C3c				
1	(14) Bio-Rad	>>>	22 Negative	71 %
	(80) DiaMed	>>>	9 Negative	29 %
Total per sample: n = 31		Success: 100 %		
2	(14) Bio-Rad	>>>	22 Negative	71 %
	(80) DiaMed	>>>	9 Negative	29 %
Total per sample: n = 31		Success: 100 %		
Total success: 100 %				
(1006) Sensitization specificity anti-C3d				
1	(14) Bio-Rad	>>>	23 Negative	61 %
	(80) DiaMed	>>>	10 Negative	26 %
	(159) Grifols	>>>	4 Negative	11 %
			1 Positive (4+)	2,6 %
Total per sample: n = 38		Success: 97 %		
2	(14) Bio-Rad	>>>	23 Negative	61 %
	(80) DiaMed	>>>	10 Negative	26 %
	(159) Grifols	>>>	3 Negative	7,9 %
			1 Positive (2+)	2,6 %
			1 Positive (3+)	2,6 %
Total per sample: n = 38		Success: 95 %		
Total success: 95 %				
(1008) Col. agglut: Quantif. IgG-DAT				
1	(14) Bio-Rad	>	1 1:30	4,5 %
		>>>	14 1:100	64 %
	(80) DiaMed	>	1 1:30	4,5 %
		>>>	6 1:100	27 %
Total per sample: n = 22		Success: 100 %		
2	(14) Bio-Rad	>>>	15 1:30	68 %
	(80) DiaMed	>>>	6 1:30	27 %
		>	1 1:100	4,5 %
Total per sample: n = 22		Success: 100 %		
Total success: 100 %				
(1009) Col. agglut: Subclass IgG1 1:1				
1	(14) Bio-Rad	>	3 Positive (1+)	13 %
		>>>	12 Positive (2+)	52 %
		>	1 Positive (3+)	4,3 %
	(80) DiaMed		1 Negative	4,3 %
		>	1 Positive (1+)	4,3 %
		>>>	3 Positive (2+)	13 %
		>	2 Positive (3+)	8,7 %
Total per sample: n = 23		Success: 96 %		
2	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	6 Negative	26 %
			1 Positive (2+)	4,3 %
Total per sample: n = 23		Success: 96 %		
Total success: 96 %				
(1010) Col. agglut: Subclass IgG1 1:100				
1	(14) Bio-Rad	>>>	15 Negative	65 %
			1 Positive (1+)	4,3 %
	(80) DiaMed	>>>	7 Negative	30 %
Total per sample: n = 23		Success: 96 %		
2	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
Total per sample: n = 23		Success: 100 %		
Total success: 96 %				
(1011) Col. agglut: Subclass IgG3 1:1				
1	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
Total per sample: n = 23		Success: 100 %		
2	(14) Bio-Rad	>>>	16 Negative	70 %
	(80) DiaMed	>>>	7 Negative	30 %
Total per sample: n = 23		Success: 100 %		
Total success: 100 %				

Test					
Sample	Group		N	Result	N _{rel}
(1012) Col. agglut: Subclass IgG3 1:100					
1	(14) Bio-Rad	>>>	16	Negative	70 %
	(80) DiaMed	>>>	7	Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %			
2	(14) Bio-Rad	>>>	16	Negative	70 %
	(80) DiaMed	>>>	7	Negative	30 %
----- Total per sample: n = 23 -----		Success: 100 %			
Total success: 100 %					
(1019) AB0 blood group					
1	(14) Bio-Rad	>>>	17	Blood group: AB	30 %
	(40) Ortho Clinical Diagnostics	>>>	2	Blood group: AB	3,6 %
	(64) Exbio Olomouc	>>>	1	Blood group: AB	1,8 %
	(80) DiaMed	>>>	2	Blood group: AB	3,6 %
	(159) Grifols	>>>	18	Blood group: AB	32 %
	(172) Immucor	>>>	5	Blood group: AB	8,9 %
	(173) Sanguin	>>>	7	Blood group: AB	13 %
	(174) IVT Imuno	>>>	3	Blood group: AB	5,4 %
	(183) Immunodiagnostic Systems	>>>	1	Blood group: AB	1,8 %
----- Total per sample: n = 56 -----		Success: 100 %			
2	(14) Bio-Rad	>>>	1	Not specified	1,8 %
		>>>	16	Blood group: 0	29 %
	(40) Ortho Clinical Diagnostics	>>>	2	Blood group: 0	3,6 %
	(64) Exbio Olomouc	>>>	1	Blood group: 0	1,8 %
	(80) DiaMed	>>>	2	Blood group: 0	3,6 %
	(159) Grifols	>>>	18	Blood group: 0	32 %
	(172) Immucor	>>>	5	Blood group: 0	8,9 %
	(173) Sanguin	>>>	7	Blood group: 0	13 %
	(174) IVT Imuno	>>>	3	Blood group: 0	5,4 %
	(183) Immunodiagnostic Systems	>>>	1	Blood group: 0	1,8 %
----- Total per sample: n = 56 -----		Success: 98 %			
Total success: 98 %					
(1020) Rh D antigen					
1	(14) Bio-Rad	>>>	22	Positive (RhD+)	39 %
	(40) Ortho Clinical Diagnostics	>>>	2	Positive (RhD+)	3,5 %
	(52) Dynex	>>>	1	Positive (RhD+)	1,8 %
	(64) Exbio Olomouc	>>>	1	Positive (RhD+)	1,8 %
	(80) DiaMed	>>>	2	Positive (RhD+)	3,5 %
	(159) Grifols	>>>	19	Positive (RhD+)	33 %
	(170) Biotest	>>>	1	Positive (RhD+)	1,8 %
	(172) Immucor	>>>	4	Positive (RhD+)	7,0 %
	(173) Sanguin	>>>	4	Positive (RhD+)	7,0 %
	(183) Immunodiagnostic Systems	>>>	1	Positive (RhD+)	1,8 %
----- Total per sample: n = 57 -----		Success: 100 %			
2	(14) Bio-Rad	>>>	22	Positive (RhD+)	39 %
	(40) Ortho Clinical Diagnostics	>>>	2	Positive (RhD+)	3,5 %
	(52) Dynex	>>>	1	Positive (RhD+)	1,8 %
	(64) Exbio Olomouc	>>>	1	Positive (RhD+)	1,8 %
	(80) DiaMed	>>>	2	Positive (RhD+)	3,5 %
	(159) Grifols	>>>	19	Positive (RhD+)	33 %
	(170) Biotest	>>>	1	Positive (RhD+)	1,8 %
	(172) Immucor	>>>	4	Positive (RhD+)	7,0 %
	(173) Sanguin	>>>	4	Positive (RhD+)	7,0 %
	(183) Immunodiagnostic Systems	>>>	1	Positive (RhD+)	1,8 %
----- Total per sample: n = 57 -----		Success: 100 %			
Total success: 100 %					
(1021) Antigen C					
1	(14) Bio-Rad	>>>	15	Positive	32 %
	(50) Merck	>>>	1	Positive	2,1 %
	(64) Exbio Olomouc	>>>	1	Positive	2,1 %
	(80) DiaMed	>>>	2	Positive	4,3 %
	(159) Grifols	>>>	21	Positive	45 %
	(172) Immucor	>>>	3	Positive	6,4 %
	(173) Sanguin	>>>	2	Positive	4,3 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	2,1 %
	(999) another manufacturer	>>>	1	Positive	2,1 %
----- Total per sample: n = 47 -----		Success: 100 %			
2	(14) Bio-Rad	>>>	15	Negative	32 %
	(50) Merck	>>>	1	Negative	2,1 %

Test	Sample	Group	N	Result	N _{rel}
	2	(64) Exbio Olomouc	>>>	1 Negative	2,1 %
		(80) DiaMed	>>>	2 Negative	4,3 %
		(159) Grifols	>>>	21 Negative	45 %
		(172) Immucor	>>>	3 Negative	6,4 %
		(173) Sanguin	>>>	2 Negative	4,3 %
		(183) Immunodiagnostic Systems	>>>	1 Negative	2,1 %
		(999) another manufacturer	>>>	1 Negative	2,1 %
	Total per sample: n = 47			Success: 100 %	
Total success: 100 %					

(1022) Antigen c

1	(0) not specified	>>>	1 Positive	2,1 %	
	(14) Bio-Rad	>>>	15 Positive	32 %	
	(50) Merck	>>>	1 Positive	2,1 %	
	(64) Exbio Olomouc	>>>	1 Positive	2,1 %	
	(80) DiaMed	>>>	2 Positive	4,3 %	
	(159) Grifols	>>>	20 Positive	43 %	
	(172) Immucor	>>>	3 Positive	6,4 %	
	(173) Sanguin	>>>	2 Positive	4,3 %	
	(183) Immunodiagnostic Systems	>>>	1 Positive	2,1 %	
(999) another manufacturer	>>>	1 Positive	2,1 %		
Total per sample: n = 47			Success: 100 %		
2	(0) not specified	>>>	1 Positive	2,1 %	
	(14) Bio-Rad	>>>	15 Positive	32 %	
	(50) Merck	>>>	1 Positive	2,1 %	
	(64) Exbio Olomouc	>>>	1 Positive	2,1 %	
	(80) DiaMed	>>>	2 Positive	4,3 %	
	(159) Grifols	>>>	20 Positive	43 %	
	(172) Immucor	>>>	3 Positive	6,4 %	
	(173) Sanguin	>>>	2 Positive	4,3 %	
	(183) Immunodiagnostic Systems	>>>	1 Positive	2,1 %	
(999) another manufacturer	>>>	1 Positive	2,1 %		
Total per sample: n = 47			Success: 100 %		
Total success: 100 %					

(1023) Antigen Cw

1	(14) Bio-Rad	>>>	5 Negative	13 %	
	(50) Merck	>>>	1 Negative	2,5 %	
	(64) Exbio Olomouc	>>>	1 Negative	2,5 %	
	(159) Grifols	>>>	21 Negative	53 %	
	(170) Biotest	>>>	1 Negative	2,5 %	
	(172) Immucor	>>>	3 Negative	7,5 %	
	(173) Sanguin	>>>	5 Negative	13 %	
	(174) IVT Imuno	>>>	2 Negative	5,0 %	
(999) another manufacturer	>>>	1 Negative	2,5 %		
Total per sample: n = 40			Success: 100 %		
2	(14) Bio-Rad	>>>	5 Negative	13 %	
	(50) Merck	>>>	1 Negative	2,5 %	
	(64) Exbio Olomouc	>>>	1 Negative	2,5 %	
	(159) Grifols	>>>	21 Negative	53 %	
	(170) Biotest	>>>	1 Negative	2,5 %	
	(172) Immucor	>>>	3 Negative	7,5 %	
	(173) Sanguin	>>>	5 Negative	13 %	
	(174) IVT Imuno	>>>	2 Negative	5,0 %	
(999) another manufacturer	>>>	1 Negative	2,5 %		
Total per sample: n = 40			Success: 100 %		
Total success: 100 %					

(1024) Antigen E

1	(14) Bio-Rad	>>>	16 Negative	33 %
	(50) Merck	>>>	1 Negative	2,1 %
	(64) Exbio Olomouc	>>>	1 Negative	2,1 %
	(80) DiaMed	>>>	2 Negative	4,2 %
	(159) Grifols	>>>	21 Negative	44 %
	(172) Immucor	>>>	3 Negative	6,3 %
	(173) Sanguin	>>>	2 Negative	4,2 %
	(183) Immunodiagnostic Systems	>>>	1 Negative	2,1 %
(999) another manufacturer	>>>	1 Negative	2,1 %	
Total per sample: n = 48			Success: 100 %	
2	(14) Bio-Rad	>>>	16 Positive	33 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT2/22 - Direct Antiglobulin Test

Deadline: 18.11.2022

Test	Sample	Group	N	Result	N _{rel}
2	(50)	Merck	>>>	1 Positive	2,1 %
	(64)	Exbio Olomouc	>>>	1 Positive	2,1 %
	(80)	DiaMed	>>>	2 Positive	4,2 %
	(159)	Grifols	>>>	21 Positive	44 %
	(172)	Immucor	>>>	3 Positive	6,3 %
	(173)	Sanguin	>>>	2 Positive	4,2 %
	(183)	Immunodiagnostic Systems	>>>	1 Positive	2,1 %
	(999)	another manufacturer	>>>	1 Positive	2,1 %
	Total per sample: n = 48		Success: 100 %		
Total success: 100 %					

(1025) Antigen e

1	(14)	Bio-Rad	>>>	15 Positive	32 %
	(50)	Merck	>>>	1 Positive	2,1 %
	(64)	Exbio Olomouc	>>>	1 Positive	2,1 %
	(80)	DiaMed	>>>	2 Positive	4,3 %
	(159)	Grifols	>>>	21 Positive	45 %
	(172)	Immucor	>>>	3 Positive	6,4 %
	(173)	Sanguin	>>>	2 Positive	4,3 %
	(183)	Immunodiagnostic Systems	>>>	1 Positive	2,1 %
	(999)	another manufacturer	>>>	1 Positive	2,1 %
Total per sample: n = 47		Success: 100 %			
2	(14)	Bio-Rad	>>>	15 Positive	32 %
	(50)	Merck	>>>	1 Positive	2,1 %
	(64)	Exbio Olomouc	>>>	1 Positive	2,1 %
	(80)	DiaMed	>>>	2 Positive	4,3 %
	(159)	Grifols	>>>	21 Positive	45 %
	(172)	Immucor	>>>	3 Positive	6,4 %
	(173)	Sanguin	>>>	2 Positive	4,3 %
	(183)	Immunodiagnostic Systems	>>>	1 Positive	2,1 %
	(999)	another manufacturer	>>>	1 Positive	2,1 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					

(1026) Antigen K

1	(14)	Bio-Rad	>>>	15 Negative	31 %
	(50)	Merck	>>>	1 Negative	2,0 %
	(64)	Exbio Olomouc	>>>	1 Negative	2,0 %
	(80)	DiaMed	>>>	2 Negative	4,1 %
	(159)	Grifols	>>>	22 Negative	45 %
	(172)	Immucor	>>>	3 Negative	6,1 %
	(173)	Sanguin	>>>	2 Negative	4,1 %
	(174)	IVT Imuno	>>>	1 Negative	2,0 %
	(183)	Immunodiagnostic Systems	>>>	1 Negative	2,0 %
(999)	another manufacturer	>>>	1 Negative	2,0 %	
Total per sample: n = 49		Success: 100 %			
2	(14)	Bio-Rad	>>>	15 Negative	31 %
	(50)	Merck	>>>	1 Negative	2,0 %
	(64)	Exbio Olomouc	>>>	1 Negative	2,0 %
	(80)	DiaMed	>>>	2 Negative	4,1 %
	(159)	Grifols	>>>	22 Negative	45 %
	(172)	Immucor	>>>	3 Negative	6,1 %
	(173)	Sanguin	>>>	2 Negative	4,1 %
	(174)	IVT Imuno	>>>	1 Negative	2,0 %
	(183)	Immunodiagnostic Systems	>>>	1 Negative	2,0 %
(999)	another manufacturer	>>>	1 Negative	2,0 %	
Total per sample: n = 49		Success: 100 %			
Total success: 100 %					

(1027) Antigen k

1	(14)	Bio-Rad	>>>	5 Positive	19 %
	(64)	Exbio Olomouc	>>>	3 Positive	12 %
	(80)	DiaMed	>>>	3 Positive	12 %
	(159)	Grifols	>>>	1 Positive	3,8 %
	(172)	Immucor	>>>	1 Positive	3,8 %
(173)	Sanguin	>>>	13 Positive	50 %	
Total per sample: n = 26		Success: 100 %			
2	(14)	Bio-Rad	>>>	5 Positive	19 %
	(64)	Exbio Olomouc	>>>	3 Positive	12 %
	(80)	DiaMed	>>>	3 Positive	12 %

EQA round: PAT2/22 - Direct Antiglobulin Test

Deadline: 18.11.2022

Test					
Sample	Group		N	Result	N _{rel}
2	(159) Grifols	>>>	1	Positive	3,8 %
	(172) Immucor	>>>	1	Positive	3,8 %
	(173) Sanguin	>>>	13	Positive	50 %
	Total per sample: n = 26		Success: 100 %		
Total success: 100 %					
(1028) Antigen M					
1	(6) APR	>>>	1	Negative	4,0 %
	(14) Bio-Rad	>>>	3	Negative	12 %
	(64) Exbio Olomouc	>>>	1	Negative	4,0 %
	(80) DiaMed	>>>	2	Negative	8,0 %
	(159) Grifols	>>>	5	Negative	20 %
	(172) Immucor	>>>	6	Negative	24 %
	(173) Sanguin	>>>	3	Negative	12 %
	(174) IVT Imuno	>>>	1	Negative	4,0 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	4,0 %
	(203) ANTITOXIN	>>>	2	Negative	8,0 %
Total per sample: n = 25		Success: 100 %			
2	(6) APR	>>>	1	Positive	4,0 %
	(14) Bio-Rad	>>>	3	Positive	12 %
	(64) Exbio Olomouc	>>>	1	Positive	4,0 %
	(80) DiaMed	>>>	2	Positive	8,0 %
	(159) Grifols	>>>	5	Positive	20 %
	(172) Immucor	>>>	6	Positive	24 %
	(173) Sanguin	>>>	3	Positive	12 %
	(174) IVT Imuno	>>>	1	Positive	4,0 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	4,0 %
	(203) ANTITOXIN	>>>	2	Positive	8,0 %
Total per sample: n = 25		Success: 100 %			
Total success: 100 %					
(1029) Antigen N					
1	(6) APR	>>>	1	Positive	4,3 %
	(14) Bio-Rad	>>>	3	Positive	13 %
	(64) Exbio Olomouc	>>>	1	Positive	4,3 %
	(80) DiaMed	>>>	2	Positive	8,7 %
	(159) Grifols	>>>	5	Positive	22 %
	(172) Immucor	>>>	4	Positive	17 %
	(173) Sanguin	>>>	3	Positive	13 %
	(174) IVT Imuno	>>>	1	Positive	4,3 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	4,3 %
	(203) ANTITOXIN	>>>	2	Positive	8,7 %
Total per sample: n = 23		Success: 100 %			
2	(6) APR	>>>	1	Positive	4,3 %
	(14) Bio-Rad	>>>	3	Positive	13 %
	(64) Exbio Olomouc	>>>	1	Positive	4,3 %
	(80) DiaMed	>>>	2	Positive	8,7 %
	(159) Grifols	>>>	5	Positive	22 %
	(172) Immucor	>>>	4	Positive	17 %
	(173) Sanguin	>>>	3	Positive	13 %
	(174) IVT Imuno	>>>	1	Positive	4,3 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	4,3 %
	(203) ANTITOXIN	>>>	2	Positive	8,7 %
Total per sample: n = 23		Success: 100 %			
Total success: 100 %					
(1030) Antigen S					
1	(6) APR	>>>	1	Positive	4,0 %
	(14) Bio-Rad	>>>	2	Positive	8,0 %
	(64) Exbio Olomouc	>>>	1	Positive	4,0 %
	(80) DiaMed	>>>	1	Positive	4,0 %
	(159) Grifols	>>>	4	Positive	16 %
	(172) Immucor	>>>	8	Positive	32 %
	(173) Sanguin	>>>	7	Positive	28 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	4,0 %
Total per sample: n = 25		Success: 100 %			
2	(6) APR	>>>	1	Positive	4,0 %
	(14) Bio-Rad	>>>	2	Positive	8,0 %
	(64) Exbio Olomouc	>>>	1	Positive	4,0 %
	(80) DiaMed	>>>	1	Positive	4,0 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT2/22 - Direct Antiglobulin Test

Deadline: 18.11.2022

Test			N	Result	N _{rel}	
Sample	Group					
2	(159) Grifols	>>>	4	Positive	16 %	
	(172) Immucor	>>>	8	Positive	32 %	
	(173) Sanguin	>>>	7	Positive	28 %	
	(183) Immunodiagnostic Systems	>>>	1	Positive	4,0 %	
	Total per sample: n = 25		Success: 100 %			
Total success: 100 %						
(1031) Antigen s						
1	(6) APR	>>>	1	Positive	5,3 %	
	(14) Bio-Rad	>>>	1	Positive	5,3 %	
	(64) Exbio Olomouc	>>>	1	Positive	5,3 %	
	(80) DiaMed	>>>	1	Positive	5,3 %	
	(159) Grifols	>>>	4	Positive	21 %	
	(172) Immucor	>>>	10	Positive	53 %	
	(173) Sanguin	>>>	1	Positive	5,3 %	
Total per sample: n = 19		Success: 100 %				
2	(6) APR	>>>	1	Negative	5,3 %	
	(14) Bio-Rad	>>>	1	Negative	5,3 %	
	(64) Exbio Olomouc	>>>	1	Negative	5,3 %	
	(80) DiaMed	>>>	1	Negative	5,3 %	
	(159) Grifols	>>>	3	Negative	16 %	
				1	Positive	5,3 %
	(172) Immucor	>>>	10	Negative	53 %	
	(173) Sanguin	>>>	1	Negative	5,3 %	
	Total per sample: n = 19		Success: 95 %			
Total success: 95 %						
(1032) Antigen P1						
1	(14) Bio-Rad	>>>	3	Positive	14 %	
	(64) Exbio Olomouc	>>>	3	Positive	14 %	
	(80) DiaMed		1	Negative	4,5 %	
			1	Positive	4,5 %	
	(159) Grifols	>>>	3	Positive	14 %	
	(172) Immucor	>>>	5	Positive	23 %	
	(173) Sanguin	>>>	6	Positive	27 %	
Total per sample: n = 22		Success: 95 %				
2	(14) Bio-Rad	>>>	2	Negative	9,1 %	
			1	Positive	4,5 %	
	(64) Exbio Olomouc	>>>	3	Negative	14 %	
	(80) DiaMed	>>>	1	Negative	4,5 %	
			1	Positive	4,5 %	
	(159) Grifols	>>>	2	Negative	9,1 %	
			1	Positive	4,5 %	
	(172) Immucor	>>>	5	Negative	23 %	
	(173) Sanguin	>>>	6	Negative	27 %	
Total per sample: n = 22		Success: 86 %				
Total success: 82 %						
(1033) Antigen Jka						
1	(14) Bio-Rad	>>>	2	Negative	7,7 %	
	(52) Dynex	>>>	2	Negative	7,7 %	
	(64) Exbio Olomouc	>>>	2	Negative	7,7 %	
	(80) DiaMed	>>>	1	Negative	3,8 %	
	(159) Grifols	>>>	4	Negative	15 %	
			2	Positive	7,7 %	
	(172) Immucor	>>>	6	Negative	23 %	
	(173) Sanguin	>>>	7	Negative	27 %	
	Total per sample: n = 26		Success: 92 %			
2	(14) Bio-Rad	>>>	2	Positive	7,7 %	
	(52) Dynex	>>>	2	Positive	7,7 %	
	(64) Exbio Olomouc	>>>	2	Positive	7,7 %	
	(80) DiaMed	>>>	1	Positive	3,8 %	
	(159) Grifols	>>>	6	Positive	23 %	
	(172) Immucor	>>>	6	Positive	23 %	
	(173) Sanguin	>>>	7	Positive	27 %	
Total per sample: n = 26		Success: 100 %				
Total success: 92 %						
(1034) Antigen Jkb						
1	(14) Bio-Rad	>>>	2	Positive	7,7 %	
	(52) Dynex	>>>	1	Positive	3,8 %	

Test	Sample	Group	N	Result	N _{rel}
1	(64)	Exbio Olomouc	>>>	2 Positive	7,7 %
	(80)	DiaMed	>>>	1 Positive	3,8 %
	(159)	Grifols	>>>	6 Positive	23 %
	(172)	Immucor	>>>	6 Positive	23 %
	(173)	Sanguin	>>>	8 Positive	31 %
	Total per sample: n = 26		Success: 100 %	-	
2	(14)	Bio-Rad	>>>	2 Positive	7,7 %
	(52)	Dynex	>>>	1 Positive	3,8 %
	(64)	Exbio Olomouc	>>>	2 Positive	7,7 %
	(80)	DiaMed	>>>	1 Positive	3,8 %
	(159)	Grifols	>>>	6 Positive	23 %
	(172)	Immucor	>>>	6 Positive	23 %
(173)	Sanguin	>>>	8 Positive	31 %	
Total per sample: n = 26		Success: 100 %	-		
Total success: 100 %					

(1035) Antigen Lea

1	(14)	Bio-Rad	>>>	3 Negative	15 %
	(64)	Exbio Olomouc	>>>	2 Negative	10 %
	(80)	DiaMed	>>>	1 Negative	5,0 %
	(159)	Grifols	>>>	3 Negative	15 %
				1 Positive	5,0 %
	(172)	Immucor	>>>	7 Negative	35 %
(173)	Sanguin	>>>	3 Negative	15 %	
Total per sample: n = 20		Success: 95 %	-		
2	(14)	Bio-Rad	>>>	3 Negative	15 %
	(64)	Exbio Olomouc	>>>	2 Negative	10 %
	(80)	DiaMed	>>>	1 Negative	5,0 %
	(159)	Grifols	>>>	2 Negative	10 %
				2 Positive	10 %
	(172)	Immucor	>>>	7 Negative	35 %
(173)	Sanguin	>>>	3 Negative	15 %	
Total per sample: n = 20		Success: 90 %	-		
Total success: 90 %					

(1036) Antigen Leb

1	(14)	Bio-Rad	>>>	3 Positive	15 %
	(64)	Exbio Olomouc	>>>	2 Positive	10 %
	(80)	DiaMed	>>>	1 Positive	5,0 %
	(159)	Grifols	>>>	4 Positive	20 %
	(172)	Immucor	>>>	7 Positive	35 %
	(173)	Sanguin	>>>	3 Positive	15 %
Total per sample: n = 20		Success: 100 %	-		
2	(14)	Bio-Rad	>>>	3 Positive	15 %
	(64)	Exbio Olomouc	>>>	2 Positive	10 %
	(80)	DiaMed	>>>	1 Positive	5,0 %
	(159)	Grifols	>>>	4 Positive	20 %
	(172)	Immucor	>>>	7 Positive	35 %
	(173)	Sanguin	>>>	3 Positive	15 %
Total per sample: n = 20		Success: 100 %	-		
Total success: 100 %					